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Third Dose of MMR Vaccine for Mumps Control
To the Editor: From the end of July through 
September 2017, a total of 26 cases of mumps 
occurred in a company of 140 military recruits in 
a single compound. Among all the soldiers on 
base, 91.4% had received two or more doses of 
the measles–mumps–rubella (MMR) vaccine be-
fore the outbreak, and the overall attack rate was 
18.6%. As a follow-up to the outbreak, we inves-
tigated whether the administration of a third 
dose of the MMR vaccine had been protective by 
stratifying our data according to the timing of 
vaccination. In line with the report by Cardemil 
et al. (Sept. 7 issue),1 the attack rate was 86% 
among the soldiers who had received no vaccina-
tion, 15.4% among those who had received two 
vaccine doses, and 8.3% among those who had 
received three vaccine doses (Table S1 in the Sup-
plementary Appendix, available with the full text 
of this letter at NEJM.org). Surprisingly, no mumps 
cases were reported among the soldiers who had 
received the third MMR dose in the year of the 
outbreak, but the attack rate was 14.3% among 
those who had received the third dose in 2015 or 
2016. Although the difference in the attack rates 
was not statistically significant, this finding may 
indicate that the timing of the administration of 
the third MMR dose may be important. Even 
among persons who have received more than two 
doses of MMR vaccine, the timely administration 
of an additional dose may be considered in an 
outbreak situation.
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To the Editor: Cardemil and colleagues report 
a university mumps outbreak that was effectively 
mitigated with a third dose of the MMR vaccine. 
The interval since the receipt of the second dose 
of MMR vaccine was related to the vulnerability 
of the mumps virus. As compared with students 
who had received the second dose of the MMR 
vaccine within the previous 2 years, those who 
had received it 13 to 15 years earlier had 7 times 
the risk of infection, and those who had received 
it 16 to 23 years earlier had 11 times the risk.
The increased attack rate among the students 
who had been vaccinated at least 13 years before 
the outbreak corresponds to findings from our 
recent retrospective epidemiologic assessment in-
volving 3811 military recruits. We found a non-
linear decline in mumps seropositivity over time, 
with a sharp decrease 13 years after the most 
recent MMR vaccine dose on the basis of anti-
body titers obtained at the outset of military 
training with the use of the BioPlex 2200 MMRV 
IgG multiplex flow immunoassay (Bio-Rad). Se-
ropositivity fell below the estimated herd-immu-
nity threshold among those last vaccinated at 
least 16 years earlier (Fig. S1 in the Supplemen-
tary Appendix, available with the full text of this 
letter at NEJM.org). Since recent mumps out-
breaks have occurred in populations that had 
been vaccinated as children,1 the findings by 
Cardemil et al. along with our data raise concern 
about the need for routine administration of 
MMR vaccine in young adults entering congre-
gated settings, such as colleges and military 
training.
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To the Editor: Cardemil et al. report that a 
third dose of the MMR vaccine offered protection 
to previously vaccinated persons in whom immu-
nity had waned. Although the administration of 
a third vaccine dose may serve as a response 
to localized outbreaks in universities, one may 
question whether it is a solution to the overall 
problem of mumps immunity. An inherent prob-
lem with the Jeryl Lynn strain of the mumps vac-
cine is that it is a different genotype from the 
mumps strains now circulating. Thus, as anti-
bodies against it wane, they may no longer pro-
tect against circulating strains.1 It may be techni-
cally feasible to mutate Jeryl Lynn to a type G 
genotype while maintaining its attenuating mu-
tations, and this should be considered.2 Another 
possibility is to develop an inactivated mumps 
vaccine based on a type G strain, which might 
give a better boost to vaccinees than a live virus 
that depends on replication to generate immunity. 
A killed mumps vaccine was developed in the 
1940s, so it is certainly possible.3 When outbreaks 
of mumps occur among vaccinees, it causes compli-
cations and decreases confidence in vaccination.
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Molecular Drug-Susceptibility Test for Tuberculosis
To the Editor: Xie et al. (Sept. 14 issue)1 present 
the evaluation of a new molecular test for the 
detection of resistance of Mycobacterium tubercu-
losis to f luoroquinolones, aminoglycosides, and 
isoniazid. In the Discussion section, the authors 
mention that one of the limitations of their study 
is that the geographic representation is limited 
to China and South Korea. The geographic origin 
of a strain of M. tuberculosis is of particular impor-
tance for the interpretation of genotypic testing 
for drug resistance. For example, it has been 
shown that strains from the Congo area can be 
erroneously interpreted as fluoroquinolone-resis-
tant with the GenoType MTBDRsl assay (Hain 
Lifescience) because of local diffusion of a clone 
carrying an A90G polymorphism in gyrA.2 For 
other antibiotics, variations that are related to 
geographic location have also been well de-
scribed.3-6 Thus, the performance of a new geno-
typic test cannot be extrapolated from one set-
ting to another but needs to be validated in each 
geographic setting.
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